Bank of New York Mellon Corp Purchases 13,581,757 Shares of Pfizer Inc. $PFE

Bank of New York Mellon Corp boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 38.9% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 48,514,971 shares of the biopharmaceutical company’s stock after acquiring an additional 13,581,757 shares during the period. Bank of New York Mellon Corp’s holdings in Pfizer were worth $1,208,023,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Horizon Financial Services LLC boosted its stake in Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. purchased a new position in shares of Pfizer in the 4th quarter worth approximately $26,000. YANKCOM Partnership bought a new position in shares of Pfizer during the 4th quarter valued at approximately $28,000. HFM Investment Advisors LLC increased its position in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares during the last quarter. Finally, Darwin Wealth Management LLC purchased a new stake in Pfizer during the 2nd quarter valued at $32,000. 68.36% of the stock is owned by institutional investors.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s oncology strategy is drawing renewed interest, helped by its newly announced global collaboration with Innovent Biologics covering up to 12 early-stage cancer programs, which could expand its long-term cancer pipeline. Pfizer Oncology Deal And Lung Cancer Data Reshape Valuation Debate
• Positive Sentiment: Analysts remain constructive overall, with Jefferies reiterating a Buy rating on PFE, reinforcing confidence in Pfizer’s valuation and outlook. Jefferies Reaffirms Their Buy Rating on Pfizer (PFE)
• Positive Sentiment: Multiple coverage pieces highlight Pfizer’s obesity and oncology pipeline as catalyst-rich for 2026, suggesting investors are focusing on upcoming data readouts and regulatory decisions rather than near-term weakness. Pfizer’s Obesity and Oncology Pipeline Sets Up a Catalyst-Rich 2026
• Positive Sentiment: Pfizer’s TALZENNA franchise received another boost after FDA approval of Foundation Medicine companion diagnostics, which may support patient identification and commercial adoption in prostate cancer. US FDA Approves FoundationOne®CDx and FoundationOne®Liquid CDx…
• Neutral Sentiment: Pfizer is scheduled to present at the Goldman Sachs Global Healthcare Conference next week, which could provide fresh updates, but the event itself is mainly a potential information catalyst. Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
• Neutral Sentiment: A new bill focused on maternal health during public health emergencies names Pfizer as a relevant company, but it is still legislative noise rather than a direct business driver for the stock. New Bill: Representative Lauren Underwood introduces H.R. 8807: Maternal Health Pandemic Response Act
• Negative Sentiment: Some coverage still frames Pfizer through the lens of the “COVID hangover” and patent-cliff concerns, underscoring why investors remain cautious despite the new pipeline optimism. Is Pfizer the Perfect Stock to Own with Kevin Warsh Heading the Fed?

Wall Street Analyst Weigh In

Several research analysts have commented on PFE shares. Morgan Stanley lifted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. UBS Group restated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a report on Wednesday, May 27th. Bank of America dropped their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Guggenheim upped their price target on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Finally, Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $28.82.

Pfizer Price Performance

Shares of PFE stock opened at $25.55 on Wednesday. Pfizer Inc. has a 52-week low of $23.06 and a 52-week high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The firm has a market capitalization of $145.62 billion, a P/E ratio of 19.50 and a beta of 0.34. The stock has a 50 day moving average price of $26.73 and a 200 day moving average price of $26.30.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. During the same period last year, the company earned $0.92 EPS. Pfizer’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.